Northcape Wealth Management’s Gilead Sciences GILD Stock Holding History

Northcape Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Buy	1,831 +21	+1%	+$2.94K	0.07%	128
2025 Q4	$222K	Sell	1,810 -182	-9%	-$22.1K	0.06%	133
2025 Q3	$221K	Buy	1,992 +5	+0.3%	+$568	0.06%	132
2025 Q2	$220K	Sell	1,987 -65	-3%	-$6.92K	0.07%	134
2025 Q1	$230K	Buy	+2,052	New	+$212K	0.07%	128
2022 Q4	–	Sell	-5,984	Closed	-$369K	–	94
2022 Q3	$369K	Buy	+5,984	New	+$377K	0.13%	107
2022 Q2	–	Sell	-5,655	Closed	-$336K	–	127
2022 Q1	$336K	Buy	+5,655	New	+$361K	0.1%	121

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Northcape Wealth Management's GILD Position: Q1 2026 in Review

Northcape Wealth Management increased its Gilead Sciences (GILD) stake by 1.2% in Q1 2026, buying an estimated $2.94K and bringing the position to 1,831 shares worth $255K. The position accounts for 0.07% of the portfolio, ranked #128.

Northcape Wealth Management first reported a position in GILD in Q1 2022 and has held it in 7 quarters since. The position peaked at $369K in Q3 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Northcape Wealth Management held 1,831 shares of Gilead Sciences worth $255K as of Q1 2026.
Northcape Wealth Management bought 21 Gilead Sciences shares in Q1 2026, an estimated $2.94K.
Gilead Sciences made up 0.07% of Northcape Wealth Management's portfolio in Q1 2026, its #128 holding.
Northcape Wealth Management first reported a position in Gilead Sciences in Q1 2022 and has held it in 7 quarters since.
Northcape Wealth Management's Gilead Sciences position peaked at $369K in Q3 2022.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Northcape Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.